drugset / Trial / NCT03958045
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.
Timeline
- Start
- 2019-09-04
- Primary completion
- 2022-11-15
- Completion
- 2022-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |